Indiana University School of Medicine researchers are developing a new, noninvasive brain stimulation technique to treat neurological disorders, including pain, traumatic brain injury (TBI), epilepsy, Parkinson’s disease, Alzheimer’s disease and more.
National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) grant has been renewed for another five years with funding expected to total $30 million from the National Institute on Aging (NIA), within the National Institutes of the Health (NIH). NCRAD is led by Tatiana Foroud, PhD, Executive Associate Dean for Research Affairs at IU School of Medicine. Since 2018, NCRAD has been among the five largest grants awarded to IU School of Medicine.
A group of researchers from Indiana University School of Medicine and Indiana University Bloomington have developed a program called Multi-Omics Graph cOnvolutional NETworks (MOGONET) that integrates omics data – such as DNA, RNA and proteins – to help researchers get a comprehensive understanding of human diseases. MOGONET can identify potential biomarkers for Alzheimer’s disease and cancers from the various omics data to predict which individuals may be at higher risk.
INDIANAPOLIS—For the fifth-straight year, Indiana University School of Medicine set a school record for research funding received from the National Institutes of Health, showcasing its continued leadership in the field of medical research.
Supported by a $1.3 million grant from the U.S. Administration for Community Living, Department of Health and Human Services, Indiana University School of Medicine and its partners have launched a 36-month venture to enhance, strengthen and expand supports for people with Alzheimer’s Disease and Related Dementias and their caregivers in 34 Indiana counties.
A veteran researcher and Indiana University School of Medicine faculty member will be taking on a new role with the Indiana Biosciences Research Institute—a leading industry-inspired applied research institute. Alan Palkowitz, PhD, was named the new president and CEO of the IBRI in an announcement on Wednesday, September 2. Palkowitz will spend 80 percent of his time at the IBRI serving in this new position, while maintaining his role at IU School of Medicine as a senior research professor of medicine and leader of the IUSM-Purdue TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center.
INDIANAPOLIS – For the fourth-straight year, Indiana University School of Medicine set a school record for research funding received from the National Institutes of Health, demonstrating national leadership in critical fields like Alzheimer’s disease and pediatrics and providing a major boost to the Indiana economy. IU School of Medicine scientists and physicians were awarded over […]
INDIANAPOLIS – Research scientists at Regenstrief Institute and Indiana University School of Medicine have conducted the first randomized controlled trial to evaluate the pros and cons of population screening for dementia. The researchers found no harm, as measured by patient reported depressive and anxiety symptoms, from screening for Alzheimer’s disease and related dementia in diverse […]